🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Wave Life Sciences, Inc. WVE R2KR3KPHARMA

Healthcare · Biotechnology · United States
Financial distress score 55/100 (Weak) — see indicators →
https://wavelifesciences.com
Company Profile ↓
$3.18
-63.70% 1Y
Mkt Cap$626.61M
P/E-2.94
P/B1.57
52W High$21.31
52W Low$3.09
Book Value$2.76
EPS (TTM)$-1.08

Company Overview

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 75.8% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.10.

Recent Developments

  • Dec 2025 Revenue of $42.73M (-60.5% YoY); net profit $-204.38M.
  • Trailing 12 Months Year-on-year growth — revenue -73.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 75.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:75.75%
1 Year:-73.90%

Stock Price Performance

1 Year:-63.70%
6 Months:-55.71%
3 Months:-46.28%
1 Month:-19.70%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$3.09 $21.31
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)32.25 · Neutral
Price Performance
1M-19.70%
3M-46.28%
6M-55.71%
1Y-63.70%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 75.8% over 5 years.

CONS

  • Trading 85.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.94
Industry PE
25.45
Forward P/E
-2.80
PEG Ratio
-
Book Value
$2.76
Price to Book
1.57
P/S
13.11
EV/EBITDA
-1.91
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
75.75%
Profit 5Y
-
Revenue (YoY)
-73.90%
Earnings (YoY)
-

Profitability & Returns

ROCE
-39.63%
ROE
-67.42%
ROA
-33.60%
Profit Margin
0.00%
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.34
EPS (TTM)
$-1.08

Balance Sheet & Liquidity

Debt/Equity
0.10
Quick Ratio
9.67
Current Ratio
9.99
Debt
$43.59M
Total Assets
$558.32M
Current Assets
$561.27M
Working Capital
$519.75M

Ownership

Promoter Holding
15.50%
Chg in Prom Hold
-0.00%
FII / Inst Holding
85.37%
Chg in FII Hold
0.09%

Financial Snapshot

Enterprise Value
$626.61M
Total Revenue (TTM)
$65.37M
EBITDA
$-214.52M
Free Cash Flow
$-128.78M
Operating Cash Flow
$-191.58M
Shares Outstanding
197.05M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 WVE Wave Life Sciences, Inc. R2KR3KPHARMA 3.18 -2.94 $626.61M 0.00% -39.63% -67.42% 75.75% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------383.00K1.10M1.31M1.10M1.42M4.88M4.49M3.62M3.03M7.63M2.93M2.40M4.16M3.03M3.45M-2.78M36.42M1.75M375.00K285.00K12.93M22.11M49.21M12.54M19.69M--9.18M8.70M7.61M17.25M38.25M2.27M
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------58.98M61.46M63.96M73.71M69.54M-
Operating Income -4.99M-7.21M-7.95M-11.64M-17.23M-18.50M-20.21M-24.67M-26.35M-31.16M-35.77M-36.57M-38.23M-48.94M-47.99M-45.62M-54.18M-60.53M-49.99M-38.66M-34.41M-43.47M-39.83M-7.61M-38.09M-42.16M-38.90M-30.29M-23.47M4.44M-34.46M-35.00M-63.91M--49.80M-52.76M-56.35M-56.47M-31.30M-73.80M
EBITDA -----------------------------------47.64M-50.56M-54.12M-54.20M-28.99M-
Interest Expense ----------------------------------------
Pretax Income -----------------------------------46.88M-50.47M-53.85M-53.18M-26.09M-
Tax Provision ----------------------------------00000-
Net Income -4.94M-7.10M-7.85M-11.56M-17.54M-18.45M-21.10M-24.60M-25.49M-30.79M-35.24M-35.89M-37.63M-37.89M-44.20M-41.94M-50.73M-56.77M-47.49M-40.53M-33.10M-42.46M-38.77M-6.23M-37.81M-41.30M-39.00M-27.41M-21.10M7.25M-31.56M-32.92M-61.78M--46.88M-50.47M-53.85M-53.18M-26.09M-69.36M
Diluted EPS -----------------------0.78-0.12-0.62-0.62-0.42-0.27-0.200.07-0.24-0.25-0.47--0.29-0.31-0.32-0.30-0.13-0.34
R&D Expense 2.13M-4.74M8.40M13.69M-14.74M19.10M20.10M-29.20M32.55M32.88M-40.11M41.60M44.59M-41.16M31.48M28.27M33.39M31.64M31.09M27.47M29.73M27.57M30.98M33.31M31.64M33.45M40.39M41.20M-40.62M43.47M45.87M-47.44M51.29M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --152.00K1.09M3.89M14.41M15.98M20.08M40.96M3.65M113.31M108.30M42.73M
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses ---------166.37M181.30M218.71M258.11M
Operating Income -3.57M-5.39M-19.30M-55.72M-102.39M-159.52M-208.32M-153.38M-127.02M-162.72M-68.00M-110.40M-215.38M
EBITDA ----------152.61M-58.79M-101.74M-206.53M
Interest Expense -------------
Pretax Income ----------161.14M-58.19M-97.01M-204.38M
Tax Provision ---------681.00K-677.00K00
Net Income -3.32M-5.23M-19.20M-55.66M-101.98M-146.65M-193.64M-149.91M-122.25M-161.82M-57.51M-97.01M-204.38M
Diluted EPS ---------2.36-2.05-0.54-0.70-1.21
R&D Expense 1.92M2.40M9.06M40.82M79.31M134.43M175.43M130.94M121.88M115.86M130.01M159.68M182.78M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --2.94M165.42M164.81M181.84M295.94M284.25M279.24M207.01M146.39M274.95M352.21M638.50M
Current Assets ----------98.54M235.37M320.39M614.81M
Cash & Equivalents 379.00K439.00K1.05M161.22M150.29M142.50M174.82M147.16M184.50M150.56M88.50M200.35M302.08M602.07M
Inventory --------------
Receivables ----------021.09M1.42M1.28M
Total Liabilities --911.00K4.06M22.07M34.36M214.72M212.64M188.59M166.63M191.48M235.32M142.69M120.14M
Current Liabilities --882.00K3.82M12.15M18.19M130.04M118.15M121.04M64.20M71.52M186.44M110.95M95.06M
Long Term Debt --------------
Total Debt ----------37.61M32.12M25.40M17.77M
Total Equity -4.58M-7.76M2.03M153.49M134.60M139.61M73.35M63.73M82.78M32.50M-45.09M39.63M209.51M518.36M
Shares Outstanding ----------86.92M119.16M153.04M187.66M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----31.93M-83.67M-22.86M-188.23M-115.98M--127.78M-19.43M-151.03M-187.49M
Investing Cash Flow ----5.56M-18.89M-9.94M-3.92M-1.34M--1.25M-1.11M-938.00K-718.00K
Financing Cash Flow ---29.12M94.37M65.09M164.40M154.54M-67.19M132.53M253.89M488.24M
Capital Expenditure -47.00K-590.00K-1.86M-5.57M-18.89M-9.94M-3.92M-1.34M--1.36M-1.11M-938.00K-718.00K
Free Cash Flow ----37.49M-102.56M-32.80M-192.15M-117.32M--129.14M-20.55M-151.96M-188.21M
Net Change in Cash ----------61.85M111.99M101.93M300.02M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % ---12,696.1%-5,102.6%-2,630.1%-1,106.7%-1,303.4%-763.9%-310.1%-4,459.3%-60.0%-101.9%-504.1%
Net Margin % ---12,631.6%-5,097.1%-2,619.6%-1,017.4%-1,211.5%-746.7%-298.4%-4,434.7%-50.8%-89.6%-478.3%
ROE % 42.7%-258.0%-12.5%-41.4%-73.0%-199.9%-303.8%-181.1%-376.2%358.9%-145.1%-46.3%-39.4%
ROCE % --262.4%-11.9%-36.5%-62.6%-96.2%-125.4%-97.0%-88.9%-217.4%-76.8%-45.8%-39.6%

Shareholding Pattern

Insiders
15.50%
Institutions
85.37%
Public Float
101.04%

Top Institutional Holders

#Holder% HeldSharesValue
1 Kennedy Capital Management, LLC - 429.12K $1.48M
2 Versant Capital Management, Inc - 1.37K $4.74K
3 MassMutual Private Wealth & Trust, FSB - 1.05K $3.63K
4 Farther Finance Advisors, Llc - 2.15K $7.43K
5 Gamma Investing LLC - 535 $1.85K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WVE

Google News Wed, 21 Oct 2026

Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5KeFo5WUxJN2dBMWN4Yjd5NER3RS1Ga240TWRyQllGOGF5ejNlc1Q2bVByWlliS2hDaVFMZW5ZamNWdVdERkkxLVB3bGhJbl85?oc=5" target="_blank">Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & H…

Google News Fri, 23 Oct 2026

Wave Life Sciences, Inc. Estimates – NASDAQ:WVE - TradingView

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBYWWZqV3JmU19WSHp3QnY4MHA2UGh6bll3OFVEa1lDYzlGcjFfWFludTBXOUppajQ2MFcwdjBkTURCT3daQlpwMV9qU0tqU2ZHbWY2T3ljdFUtYjVrdTNrUXA1SnVOZVdBTk1DdmN6c2lmU0FIUU9V?oc=5" target="_blank">Wave Li…

Google News Sat, 17 Oct 2026

Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNZUd4QkxRMFRwOUwtLUt2VXAwX3ZQWW5aY05XWkl1Q1pnS3YzNmZiWkxDVDlQNFBDRklWcVNSb3ZmVDE4TTUxaWdUS05abmptZ1VpMlRtVTZ6eUdYR2xNb3N2UG04czFWcjVLV0tqcUx1Mzh1NFM2UFlNbnZZbHJEenY2SHJycFRxb0tyQW…

Google News Mon, 19 Oct 2026

New data on medicines that act on genetic messages is coming Nov. 4 from Wave Life Sciences - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNdDZSaVM0c2ZRT1V6QUxzemo2Wk1DRmNDb2VnX0VxTFJnNS01VmpIdWsxNkVyVkZ1emdIcWhPSG5uR1RYMlMtaWRMSVE1Rjg3ZUhLN2YyN2Y1d2NXRW5jYzNVaG53cjBYUmdTR1ROWmQ4azJHd3ZDNDlXQTNuLW1RRmlKLWVVejdSSlN2SV…

Google News Mon, 18 May 2026

WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOOHozVEFEQWs4c3dGZ09iT2V3VzB5NlFmTmZMcW1SV0xIbmhMM2FITFhLUlRGYjR1SE8tRy1nUUZLcDVRZlREMV9iMjhBT1NFYktvUEtaZi03cFJuWmtHdmpuNGdKQml4WnZEU2FsWG5GQ3FIcjB1Rm92U1NlNXc5Szd5NTh5ZERuMXA2ME…

Google News hu, 15 Oct 2026

Wave Life Sciences (NasdaqGM:WVE) Stock Forecast & Analyst Predictions - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPOHo0TUh1TEFyV2xLZ0hfc2szTGEza0Jva3JoRGZOZVhhc0ZRVGQ1OGVFckN1bm9saTFydUtFVHFOSHlESHBWVWJWTk9YdE1LbVBoai13MVVTUWF4Mm9OZm43NnNCS05TRWxMck8yNDc3a09TWDh3cTE1VjFSeHJDTzNZdlZPWUt3YnlCZC…

WVE — Frequently Asked Questions

What is the current share price of Wave Life Sciences, Inc. (WVE)?

As of 2026-10-23 16:27 PDT, Wave Life Sciences, Inc. (WVE) trades at $3.18 on NasdaqGM. Its 52-week range is $3.09 to $21.31.

What is the market capitalisation of WVE?

Wave Life Sciences, Inc. (WVE) has a market capitalisation of $626.61M on NasdaqGM.

What is the P/E ratio of WVE?

WVE trades at a trailing price-to-earnings (P/E) ratio of -2.94. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.57.

What is the return on equity (ROE) of WVE?

WVE has a return on equity (ROE) of -67.42%. Its return on capital employed (ROCE) is -39.63%.

Is WVE a good stock to buy?

This page provides a data-driven analysis of Wave Life Sciences, Inc. (WVE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space